Show simple item record

dc.contributor.author
Bankova, Andriyana K.
dc.contributor.author
Pasin, Chloé
dc.contributor.author
Huang, Alice
dc.contributor.author
Cicin‐Sain, Caroline
dc.contributor.author
Epp, Selina
dc.contributor.author
Audige, Annette
dc.contributor.author
Mueller, Nicolas J.
dc.contributor.author
Nilsson, Jakob
dc.contributor.author
Vilinovszki, Oliver
dc.contributor.author
Nair, Gayathri
dc.contributor.author
Wolfensberger, Nathan
dc.contributor.author
Hockl, Philipp
dc.contributor.author
Schanz, Urs
dc.contributor.author
Trkola, Alexandra
dc.contributor.author
Kouyos, Roger
dc.contributor.author
Hasse, Barbara
dc.contributor.author
Zinkernagel, Annelies S.
dc.contributor.author
Manz, Markus G.
dc.contributor.author
Abela, Irene A.
dc.contributor.author
Müller, Antonia M. S.
dc.date.accessioned
2023-11-08T15:56:18Z
dc.date.available
2023-11-08T14:25:30Z
dc.date.available
2023-11-08T15:56:18Z
dc.date.issued
2023-04
dc.identifier.issn
0007-1048
dc.identifier.issn
1365-2141
dc.identifier.other
10.1111/bjh.18562
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/640963
dc.identifier.doi
10.3929/ethz-b-000640963
dc.description.abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation ac-tivity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Wiley
en_US
dc.rights.uri
http://creativecommons.org/licenses/by-nc/4.0/
dc.subject
allogeneic haematopoietic cell transplantation
en_US
dc.subject
severe acute respiratory syndrome coronavirus-2 (SARS- CoV- 2)
en_US
dc.subject
vaccine response
en_US
dc.title
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution-NonCommercial 4.0 International
dc.date.published
2022-11-16
ethz.journal.title
British journal of Haematology
ethz.journal.volume
201
en_US
ethz.journal.issue
1
en_US
ethz.journal.abbreviated
Br J Haematol
ethz.pages.start
58
en_US
ethz.pages.end
63
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00003 - Schulleitung und Dienste::00022 - Bereich VP Forschung / Domain VP Research::02803 - Collegium Helveticum / Collegium Helveticum
en_US
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00003 - Schulleitung und Dienste::00022 - Bereich VP Forschung / Domain VP Research::02803 - Collegium Helveticum / Collegium Helveticum
en_US
ethz.date.deposited
2023-11-08T14:25:30Z
ethz.source
FORM
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2023-11-08T15:56:19Z
ethz.rosetta.lastUpdated
2024-02-03T06:05:38Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Antibody%20response%20to%20a%20third%20SARS%E2%80%90CoV%E2%80%902%20vaccine%20dose%20in%20recipients%20of%20an%20allogeneic%20haematopoietic%20cell%20transplantation&rft.jtitle=British%20journal%20of%20Haematology&rft.date=2023-04&rft.volume=201&rft.issue=1&rft.spage=58&rft.epage=63&rft.issn=0007-1048&1365-2141&rft.au=Bankova,%20Andriyana%20K.&Pasin,%20Chlo%C3%A9&Huang,%20Alice&Cicin%E2%80%90Sain,%20Caroline&Epp,%20Selina&rft.genre=article&rft_id=info:doi/10.1111/bjh.18562&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record